As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
18 Analysts have issued a Ocular Therapeutix Inc forecast:
18 Analysts have issued a Ocular Therapeutix Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 60 60 |
0%
0%
|
|
Gross Profit | 54 54 |
1%
1%
|
|
EBITDA | -200 -200 |
127%
127%
|
EBIT (Operating Income) EBIT | -204 -204 |
123%
123%
|
Net Profit | -193 -193 |
67%
67%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Pravin Dugel |
Employees | 274 |
Founded | 2006 |
Website | www.ocutx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.